Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "大唐电信2025年11月26日资金流向"

Looking for quality documents?
external link icon
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
Portfolio includes PAT devices for real-time process monitoring, control and analysis WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc . (Nasdaq: MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices’ desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety applications. The addition of these desktop assets complements and strengthens Repligen’s differentiated PAT portfolio that provides its biopharmaceutical and CDMO customers with actionable insights to optimize development processes and improve manufacturing efficiencies. Products acquired from 908 Devices include MAVERICK and MAVEN for real-time
news icon
Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
external link icon
Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock
WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that it has commenced an underwritten public offering of $100,000,000 in shares of its common stock. In addition, Repligen Corporation expects to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 in shares of its common stock in connection with the proposed public offering. All shares of common stock will be offered by Repligen Corporation.
Repligen Corporation expects to use the net proceeds of the offering for working capital and other general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products, services and technologies. J.P. Morgan Securities LLC and Stephens Inc. are acting as joint book-running managers for the offering.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the
external link icon
Repligen to Present at Jefferies 2015 Healthcare Conference
WALTHAM, Mass., May 26, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced its upcoming presentation at the Jefferies 2015 Healthcare Conference to be held June 1-4, 2015  at the Grand Hyatt in New York. Tony J. Hunt, Repligen President and Chief Executive Officer, will present a Company overview on Wednesday, June 3, at 8:00 a.m. EDT.  A live audio webcast of this discussion will be accessible through the Investor Events section of the Company’s website. A replay of the webcast will also be accessible for a period of time following the event. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of
external link icon
Repligen Reports Third Quarter 2014 Financial Results
Product Revenue Increases 24% to $15.2 Million Product Gross Profit Increases 26% to $8.2 Million Conference Call and Webcast Today at 8:30 a.m. EST WALTHAM, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today reported financial results for its third quarter ended September 30, 2014. The Company's financial and business highlights for the third quarter and year-to-date follow, as well as updated financial guidance for the year 2014. Third Quarter Financial Highlights: Product revenue for the third quarter of 2014 was $15.2 million, an increase of 24%, compared to $12.2 million in product revenue for the third quarter of 2013. Total revenue for the third quarter of 2014 was $15.3 million, compared to $18.8 million for the third quarter of 2013. The 2013 quarter included $6.6 million in royalty and other revenue, of which $4.8 million was royalty revenue from Bristol-Myers Squibb based on its U.S. sales of Orencia ® under an agreement that expired on December
external link icon
Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report
WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Report and related reporting framework disclosures. Themed “ Perspectives on Progress ”, this report communicates the company’s progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities and Partnerships & Pathways. Also included in the 2024 Corporate Sustainability Report are detailed disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and two key reporting frameworks: the Global Reporting Initiative (GRI) Standards and Sustainability Accounting Standards Board (SASB), now part of the IFRS Sustainability Alliance. Olivier Loeillot, President and Chief Executive Officer at Repligen, said, “At Repligen, we take a pragmatic approach
external link icon
Repligen Corporation to Present at William Blair Growth Conference
WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45 th Annual Growth Stock Conference being held June 3 – 5 in Chicago. Olivier Loeillot, President and Chief Executive Officer is scheduled to present a company overview on June 3 rd at 1:20 p.m. CT. A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event. About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug
external link icon
Repligen to Present at the Stifel Healthcare Conference 2013
WALTHAM, Mass., Sept. 4, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the Stifel Healthcare Conference on Wednesday, September 11, 2013 at 3:50 p.m. EDT. The annual conference will take place September 11-12 at the Four Seasons Hotel in Boston. The Repligen presentation will be webcast live and can be accessed through the Investors section of Company's website at www.repligen.com . The webcast and slide presentation will also be archived for a period of time on the Company's website. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading
news icon
Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
external link icon
Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and integrate Novasign’s machine learning and modeling workflow into Repligen filtration systems. As part of the partnership, Repligen will invest in Novasign to help scale and expand operations. Through this collaboration, Novasign’s unique modeling workflow will be integrated into Repligen’s tangential flow filtration (TFF) systems. This will not only enhance Repligen’s digitalization journey and strengthen its portfolio of process analytical technology (PAT)-enabled systems but also unlock the potential for future advanced AI modeling within Repligen platforms. The end goal is to streamline process development, enable real-time predictive control, and significantly reduce development timelines and costs through the deployment of digital
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support